Lincoff et al., 2023)
Both BCBS-NC and BCBS-Michigan made notable weight-loss GLP-1 coverage pullbacks in the 2024-2025 period, but they affected different lines of business
Evidence level: Level C (observational comparative) suggests no increased infection liability and possible reduced risk vs SGLT2 inhibitors
The medication is licensed exclusively for type 2 diabetes management (and Wegovy for specific weight management indications), and prescribing it for off-label cosmetic or athletic enhancement is generally not appropriate, particularly amid current UK supply constraints as highlighted by DHSC and NHS England alerts
Unknown long-term safety: Long-term effects of exogenous glutathione administration are not well-studied Injection technique: Must be administered by or under the direction of a qualified provider Common Side Effects Injection site reactions: pain, redness, swelling Mild nausea Lightheadedness Transient sulfur-like odor or taste Headache Temporary changes in skin pigmentation Seek Immediate Medical Attention For Signs of severe allergic reaction: rash, itching, swelling of face/tongue/throat, severe dizziness, trouble breathing Widespread skin rash or peeling skin Chest pain or difficulty breathing Signs of liver problems: yellowing of skin or eyes, dark urine, severe fatigue Use in Pregnancy and Breastfeeding Safety has not been established
